Hikma Pharmaceuticals Plc Director/PDMR Shareholding (7823S)

TIDMHIK

RNS Number : 7823S

Hikma Pharmaceuticals Plc

13 March 2019

Notification and public disclosure of transactions by persons discharging managerial responsibilities

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Mazen Darwazah 
 2    Reason for the notification 
 a)   Position/status           Executive Vice Chairman 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             (Shares) 
       instrument, type          ID Code: GB00B0LCW083 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Market purchase of 20,000 Ordinary Shares by 
       transaction               Capital Investment & Brokerage / Jordan Ltd. 
                                 Co for and on behalf of Mazen Darwazah. 
 c)   Price(s) and              Price(s): GBP15.8198 
       volume(s)                 Volume(s): 20,000 
 d)   Aggregated information 
        *    Volume               20,000 
                                 GBP316,396.00 
 
        *    Price 
 e)   Date of the transaction   13 March 2019 
 f)   Place of the              London Stock Exchange (XLON) 
       transaction 
 

Peter Speirs

Company Secretary, responsible for releasing this announcement

[phone]

13 March 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBXGDXISBBGCX

(END) Dow Jones Newswires

March 13, 2019 09:50 ET (13:50 GMT)